Important Notice to Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Flotek Industries, Inc. (NYSE: FTK); Hub Group, Inc. (NASDAQ: HUBG); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf
PHILADELPHIA, Sept. 01, 2026 (GLOBE NEWSWIRE) --
Aardvark Therapeutics, Inc. (NASDAQ: AARD):
Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.
What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects of the Company’s lead drug candidate, ARD-101.
If you purchased Aardvark Therapeutics, Inc. (NASDAQ: AARD) shares on or shortly after the Company’s February 13, 2025 IPO, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. You are encouraged to visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.
What is Alleged? According to the recently filed securities complaint, Aardvark Therapeutics, Inc. (NASDAQ: AARD) IPO offering documents represented that ARD-101 had been “well-tolerated” in earlier clinical trials, had limited systemic absorption, and had demonstrated no serious adverse events. The complaint alleges that the offering documents were materially false or misleading because they failed to disclose that ARD-101 was less safe than investors had been led to believe and that its clinical, regulatory, and commercial prospects were therefore overstated.
The complaint further alleges that similar representations concerning ARD-101’s safety continued after the IPO. For example, Company representatives subsequently described ARD-101 as having a “very, very clean” safety profile and represented that its limited systemic exposure reduced the likelihood of side effects.
Then, on February 27, 2026, Aardvark announced that it was voluntarily pausing enrollment and dosing in the Phase 3 HERO trial after identifying reversible cardiac observations during safety monitoring in a healthy-volunteer study. Following the announcement, Aardvark’s stock price allegedly declined approximately 56%, closing at $5.47 per share on March 2, 2026.
Then, on May 14, 2026, Aardvark announced that the FDA had placed a full clinical hold on the investigational new drug application for ARD-101, including the Phase 3 HERO trial and its open-label extension. According to the complaint, Aardvark’s stock declined another 32.1% the following day, closing at $4.57 per share.
What Can You Do Now? If you purchased Aardvark shares at or shortly after the February 13, 2025 IPO, and continue to own those shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more. #AARD $AARD #Aardvark
Flotek Industries, Inc. (NYSE: FTK):
Grabar Law Office is investigating potential claims on behalf of shareholders of Flotek Industries, Inc. (NYSE: FTK).
What is This Investigation About? The investigation concerns possible breaches of fiduciary duty and other corporate governance issues relating to the Company's recently terminated Puerto Rico Electric Power Authority ("PREPA") project.
If you have continuously owned Flotek Industries, Inc. (NYSE: FTK) shares since before August 3, 2026, you may be able to pursue corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. please Visit https://grabarlaw.com/the-latest/flotek-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more. Alternatively, if you purchased shares between August 3, 2026, and August 17, 2026, you can participate in the class action.
What is Alleged? On August 26, 2026, a federal securities fraud class action was filed against Flotek Industries, Inc. (NYSE: FTK) and certain of its senior officers. The complaint alleges that Flotek made materially false and/or misleading statements and failed to disclose material information concerning a 10-year agreement associated with a 400-megawatt natural gas-fired power generation project for PREPA.
According to the complaint, Flotek announced on August 3, 2026, that it had entered into a 10-year agreement to support the PREPA project and expected the arrangement to generate approximately $400 million in potential revenue backlog. Flotek subsequently highlighted the contract in its quarterly financial results, investor materials and Form 10-Q.
The underlying class action complaint alleges, however, that there were significant questions concerning the experience, organization and financial capacity of certain members of the consortium responsible for the underlying PREPA project. The complaint further alleges that Enchanted Rock, LLC—an entity whose participation allegedly had been relied upon in evaluating the project—later stated that it was not participating in the project and that its name and signature had been used without authorization.
According to Flotek's subsequent public disclosures, the Financial Oversight and Management Board for Puerto Rico ultimately revoked its approval of the underlying power-generation contract and directed PREPA to terminate it. Flotek further disclosed that certain allegations concerning the procurement process had been referred to the Puerto Rico Department of Justice and corresponding federal authorities.
On August 19, 2026, Flotek announced that PREPA had formally terminated the underlying Power Purchase and Operating Agreement, effective immediately. According to Flotek, PREPA identified two independent grounds for termination: the consortium's failure to provide required performance security within the contractual timeframe and the Oversight Board's revocation of its approval.
What is Grabar Law Office's Investigation About? Grabar Law Office is investigating whether Flotek's directors and officers adequately discharged their fiduciary duties in connection with these events, including whether: appropriate due diligence was performed before Flotek assumed significant responsibilities in the PREPA project; Company leadership adequately investigated or responded to potential warning signs concerning the project's consortium participants; material information concerning the project was timely escalated to Flotek's Board of Directors; Flotek maintained adequate internal controls, disclosure controls and risk-management procedures concerning significant new contractual commitments; the Board appropriately oversaw Flotek's expansion into infrastructure-scale power-generation services, an area the Company itself described as an emerging line of business with limited operating history; and Flotek suffered harm as a result of any failures of oversight, disclosure, internal controls or corporate governance.
What Can Flotek Shareholders Do Now? If you have continuously owned Flotek Industries, Inc. (NYSE: FTK) shares since before August 3, 2026, please visit https://grabarlaw.com/the-latest/flotek-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can pursue corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased shares between August 3, 2026, and August 17, 2026, you can participate in the class action. #Flotek #FTK $FTK
Hub Group, Inc. (NASDAQ: HUBG):
Grabar Law Office is investigating claims on behalf of shareholders of Hub Group, Inc. (NASDAQ: HUBG).
What Is This Investigation About? The investigation concerns whether certain officers and directors of Hub Group, Inc. breached the fiduciary duties they owed to the company.
If you purchased Hub Group, Inc. (NASDAQ: HUBG), shares prior to April 28, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/hubg-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
What is Alleged? As alleged in a recently filed securities fraud class action complaint, Hub Group, Inc. (NASDAQ: HUBG), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Hub Group’s financial statements prepared for the periods from Q1 2023 to Q4 2024, including annual reports for 2023 and 2024, contained material misstatements caused by the premature and incorrect recognition of certain transactions concerning, among other things, Hub Group’s operating revenue, operating income, revenue recognition, effectiveness of internal controls and procedures, and drivers of financial results and growth; and (2) Hub Group’s financial statements prepared for the periods from Q1 2025 to Q3 2025 contained material misstatements caused by the understatement of purchased transportation costs and accounts payable concerning, among other things, Hub Group’s operating expenses, purchased transportation and warehousing expenses, operating income, effectiveness of internal disclosure controls and procedures, and drivers of financial results and growth.
What Can You Do Now? If you purchased Hub Group, Inc. (NASDAQ: HUBG), shares prior to April 28, 2023, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/hubg-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #HUBG #HubGroup #HUBG
Insulet Corporation (NASDAQ: PODD):
Grabar Law Office is investigating claims on behalf of shareholders of Insulet Corporation (NASDAQ: PODD).
What Is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased Insulet Corporation (NASDAQ: PODD) shares prior to February 21, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/insulet-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
What Is Alleged? As alleged in a recently filed federal securities fraud class action complaint, Insulet Corporation (NASDAQ: PODD), through certain of its executives, violated federal securities laws by making false and/or misleading statements and/or failed to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
The truth began to emerge on March 12, 2026, when Insulet disclosed that it had “initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring.” Then, on May 26, 2026, Insulet disclosed the “initat[ion]” of another “voluntary Medical Device Correction” (the “May 2026 MDC”), this time “for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery.”
What Can You Do Now? If you purchased Insulet Corporation (NASDAQ: PODD) shares prior to February 21, 2025, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/insulet-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #Insulet, #PODD $PODD
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com